Seeking Alpha

Roland Rick Perry's  Instablog

Roland Rick Perry
Send Message
Roland Rick Perry is the Managing Director of Institutional Analyst Inc. (IA), an independent investment research and investor relations firm, as well as editor of nine industry specific investment reviews. One of the best one mile runners to come out of the Chicago area, he attended Southern... More
My company:
Disclaimer
My blog:
Internet Stock Review
View Roland Rick Perry's Instablogs on:
  • Bio-AMD Advances Monitors For Both Wafarin/Coumadin Users And Heart Attack Victims.

    Tags: BIAD
    Jun 22 6:57 AM | Link | Comment!
  • Stem Cell Stock Review Updates Coverage On Accurexa (ACXA)

    BEVERLY HILLS, CA / ACCESSWIRE / June 12, 2015 / The Stem Cell Stock Review has updated coverage on the company and will be providing ongoing coverage. Roland Rick Perry, Editor of the Review stated "Accurexa's end goal is to provide a medical device that can save lives - not by improving the therapeutics or drugs used to treat neurological disorders including brain tumors, but rather by improving the delivery method and effectiveness of currently approved drugs - used to treat the disorders using a flexible delivery catheter." Adding, "The device called "Branchpoint" is designed to permit Clinicians to "tailor" therapeutic delivery and give physicians more precise control of the volume of therapeutics delivered and ensure that therapeutics delivered into the brain stay in the brain, avoiding the problem of reflux out to the brain surface. We are excited to update coverage as they progress towards their filing a 510k submission with the FDA."

    Accurexa's Branchpoint microinjection brain catheter can be described as a quantum leap and game changing advancement in the technology of delivering drugs and therapeutics, directly to the brain over the common syringe (or cannula), as depicted in the report. The device was recently subject of a cover story in Molecular Therapy(NYSE:R) (NYSE:MT) magazine, the official journal of the American Society for Gene & Cell Therapy. The report can be viewed at both the Stem Cell and Bioteck Stock Review websites.

    Stem Cell Stock Review Website: http://www.stemcellstockreview.com/research-reports.html

    The Biotech Stock Review Website: http://www.thebiotechstockreview.com

    About The Stem Cell Stock Review

    The Stem Stock Review website provides individual news feeds for each company on the Watch List, enabling investors to easily follow the entire group with a single visit. Each Friday we issue a weekly "head-line" wrap up of stem cell industry news via our free newsletter. Also included are links to third party industry expert websites and leading news sources such as the Life Sciences Report, Edison Research, Futurity, the Timmerman Report, Fierce Biotech, BioMed Reports, Science Daily and research reports from a broad spectrum of Wall Street sources.

    The Stem Cell Stock Review additionally has a Flipboard powered magazine which archives a collection of stem cell industry related articles from over 100 sources and can be found here: Stem Cell Stock Review Magazine: https://flipboard.com/@institution73s6/stem-cell-stock-review-8oe7m025y.

    The Stem Cell Stock Review additionally has an online Internet TV channel called Biotech Exec TV, which hosts interviews with industry and Wall Street experts.

    Biotech Exec TV: http://www.biotechexectv.com/

    About Institutional Analyst

    Institutional Analyst Inc. (IA), an independent investment research and investor relations firm. IA is a leading publisher of news, perspective and market intelligence reports on the equity markets. Working with publicly traded corporations, the firm seeks out small-cap companies which have products and/or services and management which can best be described as "best of breed." To best align itself with shareholders, IA typically seeks to have 90% of its retainer, represented by an equity stake in its client companies. When compensated for providing research reports or coverage, IA will provide all details on its website or report in a manner fully compliant with current regulatory guidelines. While we are not an impartial organization, we endeavor our best to initiate research coverage on companies which believe may perform well after initiating coverage. Founded in 1995 and based in Chicago, the heart of the trading industry, Institutional Analyst has offices in Beverly Hills, CA, Chicago IL, Delray Beach, FL and Port Jefferson, NY.

    Contact:

    Roland Rick Perry
    Managing Director, Institutional Analyst Inc.
    310-594-8062
    biotechstockreview@gmail.com

    Legal Disclaimer

    Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements.

    Institutional Analyst which owns The Stem Cell Stock Review is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release, For making specific investment decisions, readers should seek their own advice.

    Institutional Analyst which owns The Stem Cell Stock Review, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

    SOURCE: Institutional Analyst Inc.

    Jun 13 10:00 AM | Link | Comment!
  • Biotech Stock Review Updates Coverage On GeoVax ($GOVX) $0.16

    You might ask yourself, "How in the world does a company with a $0.16 stock get to Phase 2 trials, which everyone knows costs tens of millions?"

    You might also ask, "How have they been so successful in the trials and yet the stock has gone down the drain?"

    Knowing thier technology has received an amazing $54 million in grants and support from the National Institutes of Health (NIH) , might give us some clues. Let's take a look at what has transpired..

    GeoVax (OTCQB:GOVX) despite its diminutive share price and performance - is the leading small publicly traded biotech company, working on a vaccine for HIV. We define "leading" - as having gone furthest in clinical trials (Phase 2a) that is still standing, fighting and working to create a vaccine - to prevent HIV. No other small public company, even comes close to their progress.

    Furthermore, out of 100 Phase 1 trials conducted since 1992, only five progressed to Phase 2 - including GeoVax. With millions in funding from the NIH and massive research help from the HIV Vaccine Trials Network (HVTN) - GeoVax vaccines have already been successfully evaluated in nearly 500 humans, using various dosing and formulations.

    But the NIH isn't much concerned about stock prices, meeting quarterly deadlines or shareholder press releases. Their only concern is on finding a vaccine or a cure and doing everything the right way. While this explains how GeoVax got so far, it of course doesn't answer the questions; why has the stock gone down the drain and is now the time to bottom fish?

    Our answer to that is being funded by the NIH is a two edged sword.

    Yes it is a massive amount of money. Yes these grants have saved the company from having to issue tens of millions of shares. And yes the $54 million in funding and support from NIH, has enabled GeoVax to quietly leapfrog the competition.

    But not having taken money from Wall Street, has left the company's shares orphaned. So what's good for the company, isn't always good for the share price (particularly when done too quietly), though logically it should. But who said Wall Street was logical.

    IS IT TIME TO BOTTOM FISH?

    Read report below..

    Tags: GOVX, biotech, hiv, ebola
    May 29 11:37 AM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.